Annexon, Inc. (NASDAQ:ANNX) Receives $15.80 Average PT from Analysts

Annexon, Inc. (NASDAQ:ANNX) has received a consensus recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $15.80.

Several analysts have issued reports on ANNX shares. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th.

Annexon Stock Performance

Shares of ANNX opened at $2.81 on Friday. The stock has a 50-day moving average price of $4.26 and a 200 day moving average price of $5.55. Annexon has a one year low of $2.63 and a one year high of $8.40. The company has a market capitalization of $299.52 million, a P/E ratio of -2.68 and a beta of 1.07.

Institutional Trading of Annexon

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. TFG Asset Management GP Ltd raised its position in shares of Annexon by 78.5% during the 4th quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after purchasing an additional 615,645 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Annexon during the 4th quarter worth approximately $252,000. Shay Capital LLC acquired a new stake in shares of Annexon during the 4th quarter worth approximately $159,000. Sphera Funds Management LTD. acquired a new stake in shares of Annexon during the 4th quarter worth approximately $6,377,000. Finally, Rafferty Asset Management LLC raised its position in shares of Annexon by 23.5% during the 4th quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company’s stock worth $1,120,000 after purchasing an additional 41,544 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.